Point-of-care molecular diagnostics improve disease detection and resistance profiling in low-resource settings, suggesting enhanced treatment strategies.
The rising burden of neglected infectious diseases and the accelerating spread of antimicrobial resistance (AMR) demand rapid, accurate, and decentralized diagnostic solutions. Point-of-care (POC) molecular diagnostics enable early diagnosis and resistance profiling during the clinical encounter, without reliance on centralized laboratories, which is particularly important in low-resource settings. Molecular POC technologies are being developed around the following advances: isothermal nucleic acid amplification technologies, rapid polymerase chain reaction (PCR), CRISPR-based diagnostic detection technologies, nanomaterials-enabled biosensors, and microfluidic platforms for sample-to-results with near laboratory-quality accuracy within clinically relevant timeframes (typically < 30 minutes). The combination of artificial intelligence (AI) and cloud-based digital health systems supports the automated interpretation and provision of real-time surveillance and antimicrobial stewardship. Next-generation molecular POC platforms provide higher sensitivity and mechanistic insights into drug-resistance in TB, malaria, and bacterial infections. Barriers include clinical validation, cost, scalability, and equitable access. The convergence of molecular diagnostics, nanotechnology and AI-powered analytics leads to future-oriented, transformative opportunities in precision therapy areas, AMR surveillance and infectious disease preparedness.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: